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[57] ABSTRACT 
The preparation of aminoalkyl phenyl selenides and 
pharmaceutically acceptable salts thereof is disclosed 
which are useful for the treatment of hypertension and 
related vascular diseases and the treatment of nervous 
system dysfunctions. 
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AMINOALKYL PHENYL SELENIDES FOR THE 
TREATMENT OF HYPERTENSION AND 
NERVOUS SYSTEM DYSFUNCTIONS 
2 
original enzyme substrate form (e.g., back to the sele-
nide). Thus, it is suggested that the infusion of a chosen 
derivative of this invention as the enzyme substrate 
results in an oxygenation/reduction cycle initiated and 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to the synthesis of aminoalkyl 
phenyl selenides useful for the treatment of hyperten-
5 sustained by the target enzyme dopamine-beta-
hydroxylase, which operates at the expense of intracel-
lular ascorbic acid stores. This process can be used 
pharmaceutically to inhibit (reversibly) the function of 
sion and nervous system dysfunctions. 10 
2. Description of the Prior Art 
Phenolic aryl-seleno and aryl-thio compounds and 
other selenide and sulfide derivatives have been dis-
closed for use as photographic couplers. Lau, Phillip T. 
S., Arylthio (or seleno, or sulfonyl) Methyl-Substituted 15 
Phenolic Compounds As Photographic Couplers, 
Chem. Abstracts 80: 82391. Neither the structures, nor 
the use disclosed by Lau are related to the compositions 
of the present invention. 
May et al., U.S. Pat. No. 4,415,591 of Nov. 15, 1983, 20 
which patent is assigned in common herewith, the sub-
ject matter of which is incorporated herein by refer-
ence, discloses a method for treating hypertension in-
volving the administration of aminoalkyl phenyl sulfide 
derivatives; there is also disclosed a method for evaluat- 25 
ing the hypotensive potential of these compounds 
through the rate of enzymatic oxygenation by dopa-
mine-beta-hydroxylase in the presence of an electron 
donor such as hexacyanoferrate (II) or ascorbic acid; 
and pharmaceutical compositions are also disclosed 30 
which comprise aminoalkyl phenyl sulfide or a salt 
thereof in amount effective for treatment of hyperten-
sion, a monoamine oxidase inhibitor and a nontoxic 
excipient. 
As compared with the May et al. patent, this inven- 35 
tion involves specifically different pharmaceutical com-
pounds namely, aminoalkyl phenyl selenides and salts 
thereof, which have been found not only to cause sub-
stantial systemic blood pressure reduction, but may also 
provide potent clinical benefits with respect to nervous 40 
system dysfunctions and, in particular due to the un-
usual electrochemical properties of the selenoxide com-
pound produced by the enzymatic oxygenation of the 
selenide, to enable reversible inhibition of the function 
of adrenergic neurons. This reversible inhibition is due 45 
to depletion of intracellular ascorbate, as more fully 
described below in the Detailed Description of the 
Invention and Preferred Embodiments. 
While organosulfur chemistry is paralleled in a num-
ber of aspects by organoselenium chemistry, the facility 50 
of oxidation and reduction reactions can differ greatly. 
Riech, H. J. (1978), Oxidation in Organic Chemistry 
(Trahanovsky, W. ed.), Part C. pp 1-129, Academic 
Press, London and New York. For example, it has been 
reported that the monooxygenase activity of Aspergillus 55 
niger does not produce selenoxides from selenide sub-
strates, despite the ready sulfoxidation of sulfides under 
the same conditions. The invention herein is believed to 
be the first example of selenoxidation by a specific mo-
nooxygenase, namely, dopamine-beta-hydroxylase. 60 
The compounds of this invention, acting as substrates 
for the enzyme dopamine-beta-hydroxylase, consume 
two equivalents of ascorbic acid in the normal oxygena-
tion process of dopamine-beta-hydroxylase. However, 
due to the unusual electrochemical properties of the 65 
resultant selenoxide product, spontaneous consumption 
of additional equivalents of ascorbic acid accompanies 
the reduction of this selenoxide product back to the 
adrenergic neurons in several locations in the body, 
including the central nervous system, the peripheral 
nervous system, and the adrenal glands. This result is 
highly unexpected and appears to result from and be 
limited to the phenyl selenides of this invention. 
The prior art does not teach the aminoalkyl phenyl 
selenides or pharmaceutically acceptable salts thereof, 
nor the unexpected depletion of intracellular ascorbic 
acid which is characteristic of this invention. 
BRIEF SUMMARY OF THE INVENTION 
Accordingly, it is an object of this invention to pro-
vide a new class of compounds suitable for the treat-
ment of hypertension and related vascular diseases, and 
for the treatment of nervous system dysfunctions by the 
direct intrinsic activity of these compounds and by the 
metabolic products of these compounds after enzymatic 
activation. 
Another object of this invention is to provide new 
compounds which possess a phenyl selenide group lo-
cated within the drug molecule at a position which 
makes these molecules possess activity at neurochemi-
cal receptors and which makes them effective substrates 
for a specific oxygenase, dopamine-beta-hydroxylase, 
which can convert them into selenoxide species capable 
of gently modifying both neuronal function and cardio-
vascular tone. The selenide compounds as well as their 
enzyme products can interact with normal uptake and 
catabolic pathways to potentiate their effects and to aid 
in the normal elimination of these compounds from the 
body. 
An important object of this invention is to provide a 
new class of compounds displaying a new approach to 
the treatment of the pathologies of the human cardio-
vascular and nervous system. The intrinsic activities of 
the phenyl selenides of this invention are potentiated by 
their enzymatic conversion from relatively inactive 
pro-drug precursors into highly active enzyme prod-
ucts. 
These objects may be attained by treatment of an 
effective amount of aminoalkyl phenyl selenide deriva-
tive having the formula: 
*





R1-R7=H, OH, C1-C4-alkoxy, C1-C4-alkyl, F, Cl, 
Br, I; 
R6, R1=H or C1-C4-alkyl. 
(CHx)n=any straight or branched, saturated or un-
saturated alkyl chain of 10 carbons or less n= 1 to 10 
carbons and x=O,l, or 2 hydrogens; and pharmaceuti-
cally acceptable addition salts thereof. 
4,579,870 
3 4 
with steam heating. To the intensely dark red THF 
solution was added 9.84 ml (95 mmol, 1.2 eq.) of 50% 
hypophosphorous acid and the reaction was refluxed 
under argon for 6 hours, cooled, and diluted with 200 
BRIEF DESCRIPTION OF THE DRAWING 
The FIGURE of the drawing is a graphic depiction 
of the cyclic path of ascorbate oxidation by the aminoal-
kyl phenyl selenides of the present invention. 
DETAILED DESCRIPTION OF THE 
INVENTION AND PREFERRED 
EMBODIMENTS 
5 ml ofEt20 and washed with 200 ml of0.127 M NaOAc 
buffer pH 5.0 to remove the phosphoric acid by-pro-
duct. Both the Et20 and the buffer were deoxygenated 
by bubbling argon through fritted glass for over 1 hour 
The compounds used in this invention are in general 10 
parallel to the compounds disclosed in the May et al. 
U.S. Pat. No. 4,415,591 with the important distinction 
that the phenyl sulfide group of that patent is replaced 
by the phenyl selenide group of this invention to yield 
the capability for depletion of intracellular ascorbic 15 
acid. Thus, the phenyl ring can be substituted or unsub-
stituted, and the alkyl moiety between the selenium 
atom and the amino group may be any linear or 
branched, saturated or unsaturated chain of 1 to 10 
carbons. Suitable substituents for R1-Rs include H, OH, 20 
C1-C4-alkyl groups, such as methyl, ethyl, n-propyl, 
isopropyl, n-butyl, isobutyl, secbutyl, and t-butyl; 
C1-C4- alkoxy groups such as methoxy, ethoxy, n-
propoxy, isopropoxy, n-butoxy, isobutoxy, secbutoxy, 
t-butoxy, hydroxy, and halogen, such as fluorine, chlo- 25 
rine, bromine and iodine. Suitable substituents for R6, 
R1 include H, C1-C4-alkyl groups, such as those listed 
for R1-R5. Suitable groups for the alkyl moiety between 
the selenium atom and the amino group include methy-
lene, ethylene, 1,3-propylene 1,4-butylene, 1,6-hexy- 30 
Jene, octamethylene, decamethylene, 2-methyl-1,3-
propylene, 3-methyl-1,5-pentylene, 3-ethyl-1-1,5-penty-
lene, 2-ethyl-1,6-pentylene, 2-ethyl-l, 6-hexylene, 2-
ethyl-1,8-octylene, 5-methyl-1,9,nonylene, and the like. 
Suitable compounds useful in this invention include 35 
phenyl-2-aminoethyl selenide, 2-(methylamino)ethyl 
phenyl selenide, 2-(dimethylamino)ethyl phenyl sele-
nide, 2-(ethylamino)ethyl phenyl selenide, 2-(n-
propylamino)ethyl phenyl selenide, 2-(n-
butylamino)ethyl phenyl selenide, 2-aminoethyl 4- 40 
hydroxyphenyl selenide, 2-aminoethyl 3,4-dihydrox-
yphenyl selenide, 2-aminoethyl 3,5-dihydroxyphenyl 
selenide, 2-aminoethyl 4-methyl phenyl selenide, 2-
aminoethyl 2,4-dimethyl phenyl selenide, 2-amino-ethyl 
4-ethylphenyl selenide, 2-aminoethyl 4-propylphenyl 45 
selenide, 2-aminoethyl 4-butylphenyl selenide, 2-amino-
ethyl 4-methoxyphenyl selenide, 2-aminoethyl 4-ethoxy 
phenyl selenide, 2-aminoethyl 4-propoxyphenyl sele-
nide, 2-amino-ethyl 4-butoxyphenyl selenide, 2-amino-
ethyl 3,4-dimethoxy phenyl selenide, 2-aminoethyl 50 
3,4,5-trimethoxyphenyl selenide, 3-aminopropyl phenyl 
selenide, 4-aminobutyl phenyl selenide, 6-aminohexyl 
phenyl selenide, 8-aminooctyl phenyl selenide, 10-
aminodecyl phenyl selenide, 6-amino-2-ethylhexyl 
phenyl selenide, 3-amino-2-methylpropyl 3,4-dihydrox- 55 
yphenyl selenide, 4-amino-3-methylbutyl 3,4-dimethox-
yphenyl selenide, 4-methylamino-3-methylbutyl 3,4-
dimethoxyphenyl selenide, and the like. 
The compounds used in this invention may also be 
used in the form of their acid addition salts with non- 60 
toxic pharmaceutically acceptable acids. Such salts 
include the hydrochloride, sulfate, hydrobromide, ci-
trate, acetate, gluconate, and the like. 
A preferred compound is phenyl-2-aminoethyl sele-
nide and salts thereof. Phenyl-2-aminoethyl selenide 65 
(PAESe) was synthesized by employing the following 
procedure. Diphenyl diselenide, 24.707 g (79.16 mmol) 
was dissolved into 100 ml of tetrahydrofuran (THF) 
in order to prevent reoxidation of phenylselenol to 
diphenyl diselenide. The washed organic phase was 
then concentrated to yield a yellow oil (diselenide con-
taminant) with residual salt-containing water pockets. 
The crude product was pumped down to remove resid-
ual solvent prior to distillation, which yielded the de-
sired phenylselenol (12.6g, 51 % yield). pNMR (CDCl3) 
(s,lH) 1.54 d (m,5H) 7.35 d. Yields as high as 70% have 
been obtained for this reaction. 
The phenylselenol obtained was refluxed under argon 
overnight with 7.5 ml (88.45 ml, 1.1 eq.) of 2-methyl-2-
oxazoline and 3 ml of benzene. Upon cooling, the entire 
reaction solidified to a dense pale yellow solid which 
was recrystallized from benzene to yield 18.076 g (74.63 
mmol, 92.8% yield) of N-acetyl-phenyl-aminoethyl 
selenide as shiny white plates. pNMR (CDCl3) (s,3H) 
1.90 d, (m,2H) 3.08 d, (m,2H) 3.57 d J =6 Hz, (broad 
s,lH) 6.11 d, (m,5h) 7.48d. mass spec (m/e 243 molecu-
lar ion). 
The acetamide was hydrolyzed by refluxing over-
night in 100 ml of 6M HCI. The solution was then 
cooled in an ice bath and basified to pH 13 by the slow 
addition of solid NaOH, extracted with four 25 ml por-
tions of CHCl3, and the combined chloroform extracts 
were dried over anhydrous K1C03, filtered, and the 
solvent removed in vacuo to yield 15.680 g of the free 
amine (plus residual CHCh) as a clear yellow liquid. 
The hydrochloride salt was obtained by the addition of 
6.5 ml of 12 M HCl (1.05 eq) to 60 ml of a EtOH/EtiO 
(2: I) solution of the free amine. Recrystalization from 
EtOH/Et20 (2:1) yielded the final product; mp 
149.2°-150.7 ° C., loss of crystal structure at 131' C.; 
pNMR (D20) (s,4H) 3.21 d, (m,5H) 7.58 d; mass spec 
(m/e 201 molecular ion); elemental analysis for 
CsH12ClNSe THEORY C 40.61, H 5.12, N 5.92 
FOUND C 40.73, H 5.11, N 5.90. 
Other aminoalkyl phenyl selenides of the present 
invention can be synthesized by generally following the 
above procedure. For compounds in which R6 or R1 are 
those other than H, the preparation of such compounds 
involves the synthesis of the appropriately substituted 
halogenated side chain by standard methods and subse-
quent nucleophilic attack by the chosen selenide precur-
sor, with appropriate blocking procedures familiar to 
those skilled in the art. 
When compounds of this invention are used as anti-
hypertensive compounds, they may be administered 
orally, parenterally or rectally and may be formulated 
in compositions and dosage forms for such administra-
tion. In these compositions and dosage forms the com-
pounds are admixed with conventional nontoxic phar-
maceutical excipients. Solid dosage forms for oral ad-
ministration include capsules, tablets, pills, powders, 
and granules. In such solid dosage forms, the active 
compound is admixed with at least one inert diluent 
such as sucrose, lactose, or starch. Such dosage forms 
can also comprise, as is normal practice, additional 
substances other than inert diluents, e.g., lubricating 
agents such as magnesium stearate. In the case of cap-
sules, tablets, and pills, the dosage forms may also com-
5 
4,579,870 
prise buffering agents. Tablets and pills can also be 
prepared with an enteric coating. 
Liquid dosage forms for oral administration include 
pharmaceutically acceptable emulsions, solutions, sus-
pensions, syrups, and elixirs containing inert diluents 5 
commonly used in the art, such as purified water and 
alcohols. Besides inert diluents, such compositions can 
also include adjuvants, such as wetting agents, emulsify-
ing and suspending agents, and sweetening, flavoring, 
and perfuming agents. Preparations according to this 10 
invention for parenteral administration include sterile 
aqueous or nonaqueous solutions, suspension or emul-
sions. Examples of nonaqueous solvents or vehicles are 
propylene glycol, polyethylene glycol, vegetable oils 
such as olive oil and injectable organic esters such as 15 
ethyl oleate. 
6 
kyl phenyl selenides in combination with a monoamine 
oxidase inhibitor. The combination of aminoalkyl 
phenyl selenide derivatives and monoamine oxidase 
inhibitors such as clorgyline, deprenyl, nardil (phene-
thylhydrazine sulfate) or others currently in clinical use 
may protect the selenide or selenoxide product and 
therefore allow a longer active period in the body, 
resulting in an increased anti-hypertensive effect. 
Although the exact mechanism by which the com-
pounds used in the process of this invention exert their 
physiological effect is uncertain, and applicants do not 
wish to be bound by any theoretical consideration, it is 
possible that the unique biochemical action, i.e. reduc-
tion/oxidation properties of these compounds, may play 
a part in their activity alone or in combination with 
their action as false neurotransmitters as described in 
the May et al. U.S. Pat. No. 4,415,591. Other mecha-
nisms related to neuronal uptake and regulation of enzy-
matic activities may also be involved in the activities of 
Compositions for rectal administration are supposito-
ries which may contain in addition to the active sub-
stance, excipients such as cocoa butter or a suppository 
wax. 20 the compounds. 
The dosage of active ingredient in the compositions 
of this invention may be varied; however, it is necessary 
that the amount of the active ingredient be such that a 
suitable dosage form is obtained. The selected dosage 
depends upon the desired therapeutic effect, on the 25 
route of administration, and on the duration of the treat-
ment. Generally, dosage levels of between 0.5 to 100 
mg/kg of body weight daily are administered to mam-
mals to obtain effective relief of hypertension. A pre-
ferred dosage level is 1.0 to 50.0 mg/kg of body weight. 30 
The reduction of blood pressure varies with dosage 
levels. 
The effectiveness of the compounds used in the pro-
cess of this invention as anti-hypertensive agents can be 
evaluated by an enzymatic oxygenation process as dis-
closed in the aforesaid May et al. U.S. Pat. No. 
4,415,591, the subject matter of which is incorporated 
herein by reference. Using the standard substrate 2-
phenylethylamine, the carbon analog 3-phenylpropyla-
mine and the substrate phenyl-2-aminoethyl selenide of 
this invention with ascorbic acid as the electron donor, 
the values of kcat. and kcar!Km using 300 micrograms 
per milliliter of catalase were 48s-1 and 2.9x 103 
M-Is-I, respectively. 
As noted above, the enzymatic oxygenation products 
of the compounds of this invention possess unusual 
electro-chemical properties such that a unique aspect of 
the dopamine-betahydroxylase (DBH) catalyzed oxyge-
nation of aminoalkyl phenyl selenides to the corre-
sponding selenoxides is the ability of the selenoxides to 
oxidize the physiological electron donor, ascorbate, 
with the concomitant and stoichiometric reduction of 
the selenoxides back to the selenide substrate. The oxy-
genation of aminoalkyl phenyl selenide by DBH, and 
the reduction of the enzymatic product, aminoalkyl 
phenyl selenoxide back to the selenide by ascorbate 
defines a cyclic path of ascorbate oxidation where an 
excess of ascorbate is oxidized per cycle, as illustrated in 
the FIGURE of the drawing. Thus, when compounds 
of this invention are infused, it is likely that an enzy-
matic oxygenation/reduction cycle is initiated and sus-
The hydrochloride salt of phenyl-2-aminoethyl sele-
nide was administered in a commonly-used model of 
human hypertension, the spontaneously hypertensive 35 
rat (SHR). In a series of experiments, the compound 
when administered in doses ranging to 100 mg/kg, it 
was demonstrated as very potent in lowering blood 
pressure of SHR and the aforesaid variation with dos-
age levels was also demonstrated. When one group of 40 
SHR was administered intraperitonally with the com-
pound in a saline carrier at a dosage of 50 mg/kg and a 
control group was administered only with the saline 
carrier, a decrease in systemic blood pressure of approx-
imately 30% in comparison with the control animals 45 
was observed. In addition, no adverse side effects from 
the chronic administration of the compound were ob-
served when given in daily dosages over a two week 
period, while substantial blood pressure reduction was 
maintained. See Example 2 below. 50 tained by the target enzyme dopamine-beta-hydroxy-
lase. In treating hypertension in mammals by the method 
of this invention, it may not be necessary to administer 
the aminoalkyl phenyl selenide in combination with a 
monoamine oxidase inhibitor, which would have the 
effect of prolonging life of the active compounds in the 55 
body. It has been found that when the (CHx)n substitu-
ent of the compounds of the present invention· is a 
branched alkyl chain often carbons or less, the resulting 
aminoalkyl phenyl selenide is a relatively inactive pro-
drug precursor which is potentiated by its enzymatic 60 
conversion into a highly active enzyme product. Thus, 
a monoamine oxidase inhibitor may not be desirable in 
the administration of such "branched" aminoalkyl 
phenyl selenides. 
On the other hand, it has been found that compounds 65 
having a straight chain or "nonbranched" (CHx)n sub-
stituent are relatively active, and may be potentiated by 
the co-administration of such "nonbranched" aminoal-
EXAMPLE 1 
The ability of phenyl-2-aminoethyl selenoxide 
(P AESeO) to oxidize ascorbate was explored. High 
pressure liquid chromatography (HPLC) was used to 
show that the authentic selenoxide was stable at room 
temperature in the standard dopamine-beta-hydroxylase 
(DBH) reaction mixture which did not contain ascor-
bate. Upon the addition of ascorbate to a final concen-
tration of 10 mM, P AESeO disappeared from the 
HPLC chromatogram and a peak with the same reten-
tion time as phenyl-2 aminoethyl selenide (PAESe) 
appeared. As can be seen in Table I when a mixture of 
10 mM P AESeO and 5 mM ascorbate in water was 
allowed to react for 24 minutes at room temperature, 
HPLC analysis demonstrated that the concentration of 
P AESeO was diminished by 50% at the expense of 
4,579,870 
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ascorbate and that a corresponding amount of P AESe 
was formed. Similarly, the reaction of JO mM PAESeO 
and JO mM ascorbate for 60 minutes resulted in the 
complete depletion of the selenoxide and the appear-
ance of a P AESe peak, the height of which corre- 5 
sponded to 9.2 mM P AESe. These results demonstrate 
that P AESeO is stoichiometrically reduced to P AESe 
by ascorbate. In contrast to the reduction of P AESeO 
withdrawal of this compound is marked by a return of 
the animal's blood pressure to the normal hypertensive 
levels, suggesting the P AESe is catabolized and elimi-
nated by one of the normal physiological drug elimina-
tion pathways. 
Having now fully described the invention, it will be 
apparent to one of ordinary skill in the art that many 
changes and modifications can be made thereto without 
departing from the spirit or scope of the invention as set 
forth herein. 
What is claimed is: 
by ascorbate, the reaction of JO mM P AESeO and JO 
mM potassium ferrocyanide for 64 minutes did not 10 
result in the appearance of any P AESe or the loss of any 
PAESeO. 1. A method of treating hypertension in mammals 
comprising administering to the mammal an effective 
amount of an aminoalkyl phenyl selenide having the 
15 formula:. 
TABLE I 
STOICHIOMETRIC REDUCTION OF SELENOXIDE 
TO SELENIDE BY ASCORBA TE 
EXP# 
2 
Initial Composition of 
Reaction Mixture 
IO mM PAESeO 
10 mM Reduced Ascorbate 
10 mM PAESeO 
5 mM Reduced Ascorbate 
Final Reaction Products 












15 mM PAESoO 9.9 4.7 h · 
5 mM Reduced Ascorbate 25 W erem: 
------------------- R1-R5=H, OH, C1-C4-a]koxy, C1-C4-alkyl, F, Cl, 
EXAMPLE2 
The antihypertensive activity of l-phenyl-2-amino-
ethyl selenide (P AESe) was demonstrated in the follow- 30 
ing experiment. Ten male spontaneously hypertensive 
rats (SHR), at 13 weeks of age, were obtained from 
Charles River Breeding Laboratories, Inc. SHR of the 
Okamoto-Aoki strain are an inbred rat strain derived 
from a mutant progenitor in which the defect which 35 
produces hypertension has been shown to be essential, 
i.e., not renal hypertension (see Bey, P., Jung, M. J., and 
Loch-Weser, J., (1980) Brit. J. Pharmacol. 70, 571-576; 
Judy, W. V., Watanabe, A. M., Henry, D. P., Besch, H. 
R., Murphy, W. R., and Hockei, G. M., (1976) Circ. 40 
Res. 38, Suppl. I: 21-29; and references in these for 
more detail). Thus, this model of essential hypertension 
is an ideal one in which to test drugs for antihyperten-
sive activity for eventual use in the treatment of human 
essential hypertension. 45 
The animals were housed for "several weeks in an 
approved caging facility, allowed food and water ad 
libitum, and acclimated in 5- JO trials to an indirect 
systolic blood pressure monitoring protocol (tail-cuff 
plethysmographic measurement, Narco Bio-System, 50 
Inc.). The animals were divided into two groups of five 
and received either 50 mg/kg PAESe or saline, (I 
ml/kg) by subcutaneous injection at 24 hour intervals 
for seven consecutive days. Systolic blood pressure 
monitoring was performed using the indirect tail cuff 
method at one hour and three hours post-injection on 55 
each of the seven days. This testing revealed a signifi-
cant 30% reduction in the blood pressure of the PA-
ESe-treated group, apparent after the initial 24 hours 
post-injection, and maintained for seven days. 
In these experiments, the test animals were conscious 60 
at all times during the experimentation, betrayed no 
behavioral changes as a result of the drug treatment, 
and sustained no weight losses as a result of the treat-
ment. Additionally, we have found that PAESe is non-
toxic in this animal model up to the highest levels tested 65 
so far, and that its blood pressure-lowering effects are 
reversible. That is, in animals who have received 
P AESe over a 3-7 day period at 24 hour intervals, 
Br, or I; 
R6, R?=H, C1-C4-aJkyl; and 
(CHx)n =any straight or branched, saturated or unsat-
urated alkyl chain of JO carbons or Jess, n= I to JO 
carbons and x=O, l, or 2 hydrogens; and a pharma-
ceutically acceptable salt thereof. 
2. A pharmaceutical composition comprisng an ami-








Rl-Rs=H, OH, C1-C4-alkoxy, C1-C4-alkyl, F, Cl, 
Br, or I; 
R6, R?=H, C1-C4-alkyl; and 
(CHx)n =any straight or branched, saturated or unsat-
urated alkyl chain of JO carbons or Jess, n= 1 to JO 
carbons and x=O, l, or 2 hydrogens; and a pharma-
ceutically acceptable nontoxic excipient, said sele-
nide compound being present in an amount effec-
tive for treatment of hypertension in mammals. 
3. A pharmaceutical composition comprising an ami-
noalkyl phenyl selenide compound having the formula 
as in in claim 2, in an amount effective for the treatment 
of hypertension in mammals, and a clinically utilized 
monamine oxidase inhibitor, said inhibitor being se-
lected from the group consisting of clorgyline, deprenyl 
and nardil. 
4. The method as defined in claim 1 wherein the 
effective dosage of aminoalkyl phenyl selenide is from 1 
to 50 mg/kg of body weight of the mammal. 
5. The method of claim 1 wherein Rl-R7 are hydro-
gen. 
6. The method of claim 1 wherein said aminoalkyl 
phenyl selenide is phenyl-2-aminoethyl selenide. 
* * * * * 
